Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash from Investing Activities (2016 - 2025)

Dexcom (DXCM) has disclosed Cash from Investing Activities for 16 consecutive years, with $306.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 200.95% to $306.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $536.0 million, a 358.31% increase, with the full-year FY2025 number at $536.0 million, up 358.31% from a year prior.
  • Cash from Investing Activities was $306.6 million for Q4 2025 at Dexcom, up from $192.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $414.9 million in Q4 2023 to a low of -$555.9 million in Q2 2023.
  • A 5-year average of -$45.8 million and a median of -$87.9 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 1967.08% in 2021, then surged 690.69% in 2022.
  • Dexcom's Cash from Investing Activities stood at -$496.1 million in 2021, then soared by 60.87% to -$194.1 million in 2022, then soared by 313.76% to $414.9 million in 2023, then crashed by 173.2% to -$303.7 million in 2024, then surged by 200.95% to $306.6 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Cash from Investing Activities are $306.6 million (Q4 2025), $192.8 million (Q3 2025), and -$63.6 million (Q2 2025).